evERA

giredestrant

Roche Reports Positive Phase III for Giredestrant Combo After CDK4/6 Progression

Roche’s Phase III evERA trial met its co-primary endpoints, with giredestrant + everolimus delivering significant PFS benefit in ER+/HER2- metastatic breast cancer after CDK4/6 inhibitor therapy. Results mark the first positive late-stage head-to-head study of an oral SERD regimen in this setting.